NCT02934022View on ClinicalTrials.gov

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

NACompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

HIV Infection

Interventions

DRUG

Maraviroc

150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)

Trial Locations (1)

90822

VA Long Beach Healthcare System, Long Beach

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Southern California Institute for Research and Education

OTHER

NCT02934022 - Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients | Biotech Hunter | Biotech Hunter